Copanlisib

Copanlisib
Names
IUPAC name
2-Amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide
Other names
BAY 80-6946
Identifiers
3D model (JSmol)
ChemSpider
KEGG
MeSH 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide
UNII
Properties
C23H28N8O4
Molar mass 480.53 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Copanlisib (BAY 80-6946), developed by Bayer, is a selective Class I phosphoinositide 3-kinase inhibitor[1] which has shown promise in Phase I/II clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.[2]

The FDA awarded copanlisib orphan drug status for follicular lymphoma in February 2015.[3]

Phase II clinical trials are in progress for treatment of endometrial cancer,[4] diffuse large B-cell lymphoma,[5] cholangiocarcinoma,[6] and non-Hodgkin lymphoma.[7] Copanlisib in combination with R-CHOP or R-B (rituximab and bendamustine) is in a phase III trial for relapsed indolent non-Hodgkin lymphoma (NHL).[8] Two separate phase III trials are investigating the use of copanlisib in combination with rituximab for indolent NHL[9] and the other using copanlisib alone in cases of rituximab-refractory indolent NHL.[10]

References

  1. ↑ "Phase II Data of Bayer’s Novel Cancer Drug Candidate Copanlisib to be Presented". Retrieved 3 March 2015.
  2. ↑ Loguidice, Christina (8 December 2014). "Copanlisib Continues to Show Promise for Treating Indolent Lymphomas". Rare Disease Report. Retrieved 3 March 2015.
  3. ↑ http://www.prnewswire.com/news-releases/bayer-advances-clinical-development-program-for-investigational-cancer-drug-copanlisib-300065327.html
  4. ↑ https://clinicaltrials.gov/ct2/show/NCT02728258
  5. ↑ https://clinicaltrials.gov/ct2/show/NCT02391116
  6. ↑ https://clinicaltrials.gov/ct2/show/NCT02631590
  7. ↑ https://clinicaltrials.gov/ct2/show/NCT01660451
  8. ↑ https://clinicaltrials.gov/ct2/show/NCT02626455
  9. ↑ https://clinicaltrials.gov/ct2/show/NCT02367040
  10. ↑ https://clinicaltrials.gov/ct2/show/NCT02369016
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.